(PharmaNewsWire.Com, March 19, 2021 ) According to research report the perfusion systems market is projected to reach USD 1,198.8 million by 2021 from USD 989.4 million in 2016, at a CAGR of 3.9% from 2016 to 2021.
The major players in the cardiopulmonary perfusion systems market include Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), Terumo Corporation (Japan), and XENIOS AG (Germany). The major players in the ex vivo organ perfusion system market are Lifeline Scientific, Inc. (U.S.) and XVIVO Perfusion AB (Sweden), while, Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Harvard Bioscience, Inc. (U.S.), and ALA Scientific Instruments, Inc. (U.S.) are some of the leading players in the cell perfusion systems market.
The growth of the market can be attributed to the increasing prevalence of cardiovascular & respiratory diseases, initiatives by governments & NGOs to encourage organ donation, increasing investment in cell-based research, and developments in biologics manufacturing. The high cost of organ transplantation and organ supply-demand gap, however, are expected to hinder the growth of the market.
The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region. By component, the cardiopulmonary perfusion systems market is segmented into heart-lung machines, perfusion pumps, oxygenators, monitoring systems, cannulas, and other components. The oxygenators segment accounted for the largest share of the cardiopulmonary perfusion systems market in 2016.
The global cell perfusion systems market is segmented based on the type, as bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure-driven perfusion systems, and small-mammal organ perfusion systems. The bioreactor perfusion systems segment held the largest share of the cell perfusion systems market in 2016 and is projected to register the highest CAGR during the forecast period.
Based on technique, the ex vivo organ perfusion systems market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment held the largest share of the ex vivo organ perfusion systems market in 2016 and is also projected to grow at the highest CAGR during the forecast period.
Geographically, North America is estimated to account for the largest share of the global market, followed by Europe. The Asia-Pacific region is expected to witness the highest growth in the market during the forecast period. This growth will be particularly centered on China, Japan, and India.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
